Clinical Trial

DERIVO® 2heal® Study: Clinical Safety and Efficacy of the DERIVO® 2heal® Embolisation Device

Study acronym: REheal
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 4, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
To analyse the clinical safety and efficacy of the DERIVO® 2heal® Embolisation Device in the standard clinical routine of flow diversion treatment with respect to the mid- and long-term clinical and angiographic outcomes.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2022-09-14; most recent amendment 2025-08-27.
Status change: Not Yet Recruiting → Recruiting 2023-02-09
Trial Details
NCT Number NCT05543447
Lead Sponsor Acandis GmbH
Conditions Intracranial Aneurysm, Flow Diverter
Enrollment 158 participants
Start Date 2022-12-15
Primary Completion 2025-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2025-09-04